Functional deficiencies of sulfite oxidase: Differential diagnoses in neonates presenting with intractable seizures and cystic encephalomalacia


Autoria(s): SASS, Joern Oliver; GUNDUZ, Aysegul; FUNAYAMA, Carolina Araujo Rodrigues; KORKMAZ, Baris; PINTO, Kylvia Giselle Dantas; TUYSUZ, Beyhan; SANTOS, Leticia Yanasse Dos; TASKIRAN, Emine; TURCATO, Marlene de Fatima; LAM, Ching-Wan; REISS, Jochen; WALTER, Melanie; YALCINKAYA, Cengiz; CAMELO JUNIOR, Jose Simon
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2010

Resumo

Sulfite oxidase is a mitochondrial enzyme encoded by the SUOX gene and essential for the detoxification of sulfite which results mainly from the catabolism of sulfur-containing amino acids. Decreased activity of this enzyme can either be due to mutations in the SUOX gene or secondary to defects in the synthesis of its cofactor, the molybdenum cofactor. Defects in the synthesis of the molybdenum cofactor are caused by mutations in one of the genes MOCS1, MOCS2, MOCS3 and GEPH and result in combined deficiencies of the enzymes sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase. Although present in many ethnic groups, isolated sulfite oxidase deficiency and molybdenum cofactor deficiency are rare inborn errors of metabolism, which makes awareness of key clinical and laboratory features of affected individuals crucial for early diagnosis. We report clinical, radiologic, biochemical and genetic data on a Brazilian and on a Turkish child with sulfite oxidase deficiency due to the isolated defect and impaired synthesis of the molybdenum cofactor, respectively. Both patients presented with early onset seizures and neurological deterioration. They showed no sulfite oxidase activity in fibroblasts and were homozygous for the mutations c.1136A>G in the SUOX gene and c.667insCGA in the MOCS1 gene, respectively. Widely available routine laboratory tests such as assessment of total homocysteine and uric acid are indicated in children with a clinical presentation resembling that of hypoxic ischemic encephalopathy and may help in obtaining a tentative diagnosis locally, which requires confirmation by specialized laboratories. (C) 2009 Published by Elsevier B.V.

Jurgen Manchot Stiftung (Dusseldorf, Germany)

Identificador

BRAIN & DEVELOPMENT, v.32, n.7, p.544-549, 2010

0387-7604

http://producao.usp.br/handle/BDPI/24799

10.1016/j.braindev.2009.09.005

http://dx.doi.org/10.1016/j.braindev.2009.09.005

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE BV

Relação

Brain & Development

Direitos

restrictedAccess

Copyright ELSEVIER SCIENCE BV

Palavras-Chave #Sulfite #Molybdenum #Seizures #Homocysteine #Sulfocysteine #Uric acid #Xanthine #Hypoxanthine #Hypoxic-ischemic injury #MOLYBDENUM COFACTOR DEFICIENCY #MAGNETIC-RESONANCE-SPECTROSCOPY #DIETARY THERAPY #MUTATION #BIOSYNTHESIS #PRECURSOR #Clinical Neurology
Tipo

article

original article

publishedVersion